# Compare GHK-Cu and GLOW — Skin & Aesthetics Peptides — Peptide Bounce Balm

> Side-by-side comparison of GHK-Cu and the GLOW research blend across peptide class, most-studied application, evidence base, administration studied, regulatory status, and key caution.

Where the single copper-tripeptide and the three-peptide blend converge, where they diverge, and — most importantly — how far the evidence behind each actually reaches.

## The short version

This page lines up [GHK-Cu](/ghk-cu) and [GLOW](/glow) on the dimensions that matter most when reading skin and aesthetics peptide research: molecule type, primary study context, how strong the evidence is, how each was administered in studies, regulatory and anti-doping standing, and the single biggest caution each carries. The headline is simple. GHK-Cu has the most peer-reviewed topical human data of any peptide on this desk — but still in small trials, with a real delivery problem. GLOW's skin claim rests on GHK-Cu's record; the other two constituents add a tissue-repair rationale from preclinical work, and the combination itself has never been tested. Neither is an approved medicine, and neither is presented here with a human dose.

## The comparison matrix

| Dimension | GHK-Cu | GLOW (research blend) |
| --- | --- | --- |
| Peptide class | Copper-binding tripeptide / copper tripeptide-1 (3 aa + Cu²⁺ ion) | Multi-peptide co-formulation: copper tripeptide (GHK-Cu) + gastric pentadecapeptide (BPC-157) + thymosin beta-4 fragment (TB-500) |
| Most-studied in | Skin regeneration, matrix synthesis, hair follicle biology | No controlled blend study; skin claim extrapolated from GHK-Cu constituent; BPC-157 and TB-500 studied in tendon/gut/muscle repair |
| Evidence base (model) | In vitro fibroblasts + small human topical trials + 1 human RCT (combination) [1][3][4] | Narrative review naming all three constituents [8]; 3 small BPC-157 human pilots [9]; GHK-Cu topical data as the skin anchor [4] |
| Administration studied | Topical; ex vivo transdermal penetration; cosmetic cream and serum [1][5] | Injectable blend (subcutaneous, community-reported); no controlled blend study at any route |
| Regulatory / WADA status | Topical cosmetic ingredient (legal); systemic use unapproved; not WADA-listed (catch-all S0 applicable) | Not approved; TB-500 constituent is WADA S2 prohibited at all times; BPC-157 flagged by FDA as not eligible for pharmacy compounding |
| Key caution | Poor skin permeability; topical evidence is small-trial; systemic use has no validated human PK [1] | No controlled blend study; inherits BPC-157's investigational status; TB-500 WADA prohibition; pro-angiogenic concern in cancer [8][9][10] |

## Peptide class

The structural gap between the two entries is considerable. GHK-Cu is a defined single molecule — a 3-amino-acid peptide chelated to one copper ion, MW ~402.9 Da — with a CAS number, a chemical structure, and a cosmetic-ingredient listing. GLOW is a co-formulation of three structurally dissimilar peptides: GHK-Cu at ~403 Da, BPC-157 at ~1419 Da, and TB-500 at ~889 Da. They differ in molecular weight by a factor of roughly four, and their clearance rates, stability profiles, and receptor targets are entirely different. The blend has not been characterized as a combined pharmacological entity.

## Most-studied in

GHK-Cu's home territory is the skin and extracellular matrix — fibroblast collagen synthesis, dermal matrix remodeling, hair follicle biology, and wound repair [4][6]. GLOW's claimed territory is broader (skin aesthetics plus tissue and joint repair), but the evidence for that breadth is almost entirely extrapolated from its individual constituents. BPC-157 is most studied in rodent tendon, gut, and muscle-repair models [8][9]; TB-500's evidence mostly belongs to full-length thymosin beta-4 in cardiac, corneal, and CNS models rather than the marketed fragment. No study has tested the three peptides together on a skin endpoint.

## Evidence base (model)

This is where the two genuinely separate. GHK-Cu has multiple small human topical trials, an ex vivo transdermal penetration study, a gene-expression analysis, and a 45-patient placebo-controlled RCT of a GHK-containing combination formulation for hair growth [1][3][4][5]. GLOW has none of that at the blend level. The nearest thing is a 2026 Sports Medicine narrative review that names all three constituents in one paper — and whose conclusion is that unapproved peptides like these have sparse human safety data and should be approached with caution [8]. BPC-157 specifically has only three small human pilots [9]. For GLOW, the evidence base is GHK-Cu's plus a preclinical rationale for the other two, not a blend-level dataset.

## Administration studied

GHK-Cu is studied topically — in cosmetic formulations, in ex vivo skin-penetration work, and in trials using delivery-enhanced vehicles — and its human data are entirely from that surface route [1][5]. GLOW is described by research suppliers and community users as an injectable blend administered subcutaneously. No controlled study has tested GLOW at any dose or route, so its administration is defined by community practice rather than clinical trial.

## Regulatory and WADA status

Topical GHK-Cu (copper tripeptide-1) is a legal cosmetic ingredient in the US, EU, and UK. Injectable or systemic GHK-Cu has no approved indication. The WADA Prohibited List does not currently itemize GHK-Cu by name, though the catch-all S0 category can apply to any non-approved pharmacological substance. For GLOW, the binding constraint is TB-500: as a synthetic fragment of thymosin beta-4, it falls under WADA's S2 prohibition (peptide hormones, growth factors, growth factor mimetics and related substances), banned at all times, in and out of competition [8]. BPC-157 was also identified by the FDA in 2023 as not eligible for pharmacy compounding pending further evaluation.

## Key caution

For GHK-Cu, the defining limit is its own delivery: the peptide penetrates intact skin poorly (clogP -2.24), and the majority of evidence is from small trials where formulation design was the real variable [1]. The gene-expression claims are large but rest on computational analyses from a concentrated research group [2]. For GLOW, the key caution is structural: a blend with no controlled trial at any level, whose skin claim is an inference from one constituent's topical data, that carries a WADA prohibition via the TB-500 component, and whose combination pharmacokinetics have never been characterized [8][9][10]. Read together, the lesson is that the single-molecule story matters before any stack-level claim can be evaluated on its own terms.

---

A literature desk for skin-peptide research — citations drawn from the peer-reviewed record, not a product and not a prescription.